nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Ethanolamine Oleate—Orlistat—type 2 diabetes mellitus	0.412	1	CrCrCtD
Alprostadil—SLCO2B1—Tolbutamide—type 2 diabetes mellitus	0.133	0.45	CbGbCtD
Alprostadil—ABCC4—Nateglinide—type 2 diabetes mellitus	0.0866	0.292	CbGbCtD
Alprostadil—SLCO2B1—Glyburide—type 2 diabetes mellitus	0.0766	0.258	CbGbCtD
Alprostadil—PTGIR—artery—type 2 diabetes mellitus	0.00306	0.0895	CbGeAlD
Alprostadil—PTGIR—endothelium—type 2 diabetes mellitus	0.00258	0.0756	CbGeAlD
Alprostadil—PTGER1—kidney—type 2 diabetes mellitus	0.00168	0.0492	CbGeAlD
Alprostadil—PTGER1—pancreas—type 2 diabetes mellitus	0.00167	0.0489	CbGeAlD
Alprostadil—PTGER2—adipose tissue—type 2 diabetes mellitus	0.0016	0.0468	CbGeAlD
Alprostadil—SLCO2A1—islet of Langerhans—type 2 diabetes mellitus	0.00128	0.0376	CbGeAlD
Alprostadil—SLCO3A1—retina—type 2 diabetes mellitus	0.00111	0.0324	CbGeAlD
Alprostadil—PTGIR—cardiovascular system—type 2 diabetes mellitus	0.00106	0.0311	CbGeAlD
Alprostadil—PTGIR—kidney—type 2 diabetes mellitus	0.00104	0.0304	CbGeAlD
Alprostadil—SLCO2A1—nephron tubule—type 2 diabetes mellitus	0.00103	0.0303	CbGeAlD
Alprostadil—PTGIR—pancreas—type 2 diabetes mellitus	0.00103	0.0302	CbGeAlD
Alprostadil—ABCC5—retina—type 2 diabetes mellitus	0.001	0.0294	CbGeAlD
Alprostadil—ABCC5—nephron tubule—type 2 diabetes mellitus	0.000946	0.0277	CbGeAlD
Alprostadil—PTGIR—adipose tissue—type 2 diabetes mellitus	0.000937	0.0274	CbGeAlD
Alprostadil—SLCO3A1—kidney—type 2 diabetes mellitus	0.000918	0.0268	CbGeAlD
Alprostadil—SLCO2A1—kidney—type 2 diabetes mellitus	0.000909	0.0266	CbGeAlD
Alprostadil—SLCO2A1—pancreas—type 2 diabetes mellitus	0.000903	0.0264	CbGeAlD
Alprostadil—SLCO3A1—cortex of kidney—type 2 diabetes mellitus	0.000894	0.0261	CbGeAlD
Alprostadil—SLCO2A1—cortex of kidney—type 2 diabetes mellitus	0.000885	0.0259	CbGeAlD
Alprostadil—SLCO3A1—adipose tissue—type 2 diabetes mellitus	0.000827	0.0242	CbGeAlD
Alprostadil—SLCO2A1—adipose tissue—type 2 diabetes mellitus	0.000819	0.024	CbGeAlD
Alprostadil—ABCC5—adipose tissue—type 2 diabetes mellitus	0.000749	0.0219	CbGeAlD
Alprostadil—PTGIR—liver—type 2 diabetes mellitus	0.000657	0.0192	CbGeAlD
Alprostadil—ABCC4—nephron tubule—type 2 diabetes mellitus	0.000656	0.0192	CbGeAlD
Alprostadil—SLCO2B1—kidney—type 2 diabetes mellitus	0.000651	0.019	CbGeAlD
Alprostadil—SLCO2B1—adipose tissue—type 2 diabetes mellitus	0.000586	0.0172	CbGeAlD
Alprostadil—SLCO3A1—liver—type 2 diabetes mellitus	0.00058	0.017	CbGeAlD
Alprostadil—ABCC4—kidney—type 2 diabetes mellitus	0.000576	0.0169	CbGeAlD
Alprostadil—SLCO2A1—liver—type 2 diabetes mellitus	0.000575	0.0168	CbGeAlD
Alprostadil—ABCC4—pancreas—type 2 diabetes mellitus	0.000572	0.0167	CbGeAlD
Alprostadil—ABCC4—cortex of kidney—type 2 diabetes mellitus	0.000561	0.0164	CbGeAlD
Alprostadil—ABCC5—liver—type 2 diabetes mellitus	0.000525	0.0154	CbGeAlD
Alprostadil—Dinoprostone—CYP11A1—type 2 diabetes mellitus	0.000523	0.357	CrCbGaD
Alprostadil—ABCC4—adipose tissue—type 2 diabetes mellitus	0.000519	0.0152	CbGeAlD
Alprostadil—Ethanolamine Oleate—CYP2E1—type 2 diabetes mellitus	0.000413	0.282	CrCbGaD
Alprostadil—SLCO2B1—liver—type 2 diabetes mellitus	0.000411	0.012	CbGeAlD
Alprostadil—ABCC4—liver—type 2 diabetes mellitus	0.000364	0.0107	CbGeAlD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—type 2 diabetes mellitus	0.000336	0.23	CrCbGaD
Alprostadil—Dinoprostone—CYP1A2—type 2 diabetes mellitus	0.000192	0.131	CrCbGaD
Alprostadil—Back pain—Orlistat—type 2 diabetes mellitus	0.000122	0.000827	CcSEcCtD
Alprostadil—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000121	0.000824	CcSEcCtD
Alprostadil—Visual impairment—Irbesartan—type 2 diabetes mellitus	0.000121	0.000823	CcSEcCtD
Alprostadil—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000121	0.000822	CcSEcCtD
Alprostadil—Cough—Gliclazide—type 2 diabetes mellitus	0.000121	0.000822	CcSEcCtD
Alprostadil—Abdominal pain—Glimepiride—type 2 diabetes mellitus	0.000121	0.000821	CcSEcCtD
Alprostadil—Abdominal pain—Sitagliptin—type 2 diabetes mellitus	0.00012	0.000818	CcSEcCtD
Alprostadil—Convulsion—Gliclazide—type 2 diabetes mellitus	0.00012	0.000816	CcSEcCtD
Alprostadil—Hypertension—Gliclazide—type 2 diabetes mellitus	0.00012	0.000813	CcSEcCtD
Alprostadil—Rhinitis—Losartan—type 2 diabetes mellitus	0.000119	0.000806	CcSEcCtD
Alprostadil—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000118	0.000801	CcSEcCtD
Alprostadil—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000118	0.0008	CcSEcCtD
Alprostadil—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000118	0.0008	CcSEcCtD
Alprostadil—Hypotension—Glyburide—type 2 diabetes mellitus	0.000118	0.0008	CcSEcCtD
Alprostadil—Hypoaesthesia—Losartan—type 2 diabetes mellitus	0.000118	0.0008	CcSEcCtD
Alprostadil—Nausea—Repaglinide—type 2 diabetes mellitus	0.000118	0.000799	CcSEcCtD
Alprostadil—Asthenia—Glipizide—type 2 diabetes mellitus	0.000118	0.000798	CcSEcCtD
Alprostadil—Pharyngitis—Losartan—type 2 diabetes mellitus	0.000118	0.000798	CcSEcCtD
Alprostadil—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000117	0.000796	CcSEcCtD
Alprostadil—Flushing—Irbesartan—type 2 diabetes mellitus	0.000117	0.000793	CcSEcCtD
Alprostadil—Discomfort—Gliclazide—type 2 diabetes mellitus	0.000117	0.000792	CcSEcCtD
Alprostadil—Erythema—Metformin—type 2 diabetes mellitus	0.000116	0.000788	CcSEcCtD
Alprostadil—Pruritus—Glipizide—type 2 diabetes mellitus	0.000116	0.000787	CcSEcCtD
Alprostadil—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000115	0.000784	CcSEcCtD
Alprostadil—Syncope—Valsartan—type 2 diabetes mellitus	0.000114	0.000776	CcSEcCtD
Alprostadil—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000114	0.000772	CcSEcCtD
Alprostadil—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000113	0.000765	CcSEcCtD
Alprostadil—Infection—Gliclazide—type 2 diabetes mellitus	0.000112	0.000764	CcSEcCtD
Alprostadil—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000112	0.000761	CcSEcCtD
Alprostadil—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000112	0.000761	CcSEcCtD
Alprostadil—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000112	0.000758	CcSEcCtD
Alprostadil—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000111	0.000757	CcSEcCtD
Alprostadil—Cough—Valsartan—type 2 diabetes mellitus	0.000111	0.000755	CcSEcCtD
Alprostadil—Renal failure—Ramipril—type 2 diabetes mellitus	0.000111	0.000755	CcSEcCtD
Alprostadil—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000111	0.000755	CcSEcCtD
Alprostadil—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000111	0.000754	CcSEcCtD
Alprostadil—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.000111	0.000753	CcSEcCtD
Alprostadil—Thrombocytopenia—Gliclazide—type 2 diabetes mellitus	0.000111	0.000753	CcSEcCtD
Alprostadil—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00011	0.00075	CcSEcCtD
Alprostadil—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.00011	0.000747	CcSEcCtD
Alprostadil—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.00011	0.000746	CcSEcCtD
Alprostadil—Cough—Orlistat—type 2 diabetes mellitus	0.00011	0.000746	CcSEcCtD
Alprostadil—Flushing—Losartan—type 2 diabetes mellitus	0.00011	0.000746	CcSEcCtD
Alprostadil—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00011	0.000745	CcSEcCtD
Alprostadil—Erythema—Irbesartan—type 2 diabetes mellitus	0.00011	0.000744	CcSEcCtD
Alprostadil—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000109	0.000743	CcSEcCtD
Alprostadil—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000109	0.000742	CcSEcCtD
Alprostadil—Convulsion—Orlistat—type 2 diabetes mellitus	0.000109	0.000741	CcSEcCtD
Alprostadil—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000109	0.00074	CcSEcCtD
Alprostadil—Abdominal pain—Bromocriptine—type 2 diabetes mellitus	0.000109	0.00074	CcSEcCtD
Alprostadil—Dizziness—Glipizide—type 2 diabetes mellitus	0.000108	0.000736	CcSEcCtD
Alprostadil—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000108	0.000734	CcSEcCtD
Alprostadil—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000107	0.000729	CcSEcCtD
Alprostadil—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000106	0.000722	CcSEcCtD
Alprostadil—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000106	0.00072	CcSEcCtD
Alprostadil—Sinusitis—Ramipril—type 2 diabetes mellitus	0.000106	0.00072	CcSEcCtD
Alprostadil—Discomfort—Orlistat—type 2 diabetes mellitus	0.000106	0.000719	CcSEcCtD
Alprostadil—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000106	0.000718	CcSEcCtD
Alprostadil—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000105	0.000715	CcSEcCtD
Alprostadil—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000105	0.000712	CcSEcCtD
Alprostadil—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000105	0.00071	CcSEcCtD
Alprostadil—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000104	0.000708	CcSEcCtD
Alprostadil—Syncope—Metformin—type 2 diabetes mellitus	0.000104	0.000707	CcSEcCtD
Alprostadil—Oedema—Valsartan—type 2 diabetes mellitus	0.000104	0.000706	CcSEcCtD
Alprostadil—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000104	0.000705	CcSEcCtD
Alprostadil—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000104	0.000705	CcSEcCtD
Alprostadil—Infection—Valsartan—type 2 diabetes mellitus	0.000103	0.000702	CcSEcCtD
Alprostadil—Rash—Glipizide—type 2 diabetes mellitus	0.000103	0.000701	CcSEcCtD
Alprostadil—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000103	0.000701	CcSEcCtD
Alprostadil—Erythema—Losartan—type 2 diabetes mellitus	0.000103	0.0007	CcSEcCtD
Alprostadil—Oedema—Orlistat—type 2 diabetes mellitus	0.000103	0.000698	CcSEcCtD
Alprostadil—Headache—Glipizide—type 2 diabetes mellitus	0.000103	0.000697	CcSEcCtD
Alprostadil—Shock—Valsartan—type 2 diabetes mellitus	0.000102	0.000695	CcSEcCtD
Alprostadil—Infection—Orlistat—type 2 diabetes mellitus	0.000102	0.000693	CcSEcCtD
Alprostadil—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000102	0.000693	CcSEcCtD
Alprostadil—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000102	0.000691	CcSEcCtD
Alprostadil—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000101	0.000687	CcSEcCtD
Alprostadil—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000101	0.000686	CcSEcCtD
Alprostadil—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000101	0.000686	CcSEcCtD
Alprostadil—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000101	0.000684	CcSEcCtD
Alprostadil—Hypertension—Metformin—type 2 diabetes mellitus	0.0001	0.00068	CcSEcCtD
Alprostadil—Nervousness—Losartan—type 2 diabetes mellitus	0.0001	0.00068	CcSEcCtD
Alprostadil—Skin disorder—Orlistat—type 2 diabetes mellitus	9.98e-05	0.000678	CcSEcCtD
Alprostadil—Back pain—Losartan—type 2 diabetes mellitus	9.97e-05	0.000677	CcSEcCtD
Alprostadil—Abdominal pain—Glyburide—type 2 diabetes mellitus	9.97e-05	0.000677	CcSEcCtD
Alprostadil—Dyspepsia—Gliclazide—type 2 diabetes mellitus	9.97e-05	0.000677	CcSEcCtD
Alprostadil—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	9.94e-05	0.000675	CcSEcCtD
Alprostadil—Muscle spasms—Losartan—type 2 diabetes mellitus	9.91e-05	0.000673	CcSEcCtD
Alprostadil—Asthenia—Bromocriptine—type 2 diabetes mellitus	9.9e-05	0.000672	CcSEcCtD
Alprostadil—Headache—Pioglitazone—type 2 diabetes mellitus	9.83e-05	0.000668	CcSEcCtD
Alprostadil—Syncope—Irbesartan—type 2 diabetes mellitus	9.82e-05	0.000667	CcSEcCtD
Alprostadil—Visual impairment—Ramipril—type 2 diabetes mellitus	9.78e-05	0.000664	CcSEcCtD
Alprostadil—Discomfort—Metformin—type 2 diabetes mellitus	9.76e-05	0.000663	CcSEcCtD
Alprostadil—Nausea—Glipizide—type 2 diabetes mellitus	9.73e-05	0.000661	CcSEcCtD
Alprostadil—Hypotension—Valsartan—type 2 diabetes mellitus	9.72e-05	0.00066	CcSEcCtD
Alprostadil—Pain—Gliclazide—type 2 diabetes mellitus	9.68e-05	0.000657	CcSEcCtD
Alprostadil—Rash—Glimepiride—type 2 diabetes mellitus	9.64e-05	0.000654	CcSEcCtD
Alprostadil—Dermatitis—Glimepiride—type 2 diabetes mellitus	9.63e-05	0.000654	CcSEcCtD
Alprostadil—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	9.63e-05	0.000654	CcSEcCtD
Alprostadil—Rash—Sitagliptin—type 2 diabetes mellitus	9.61e-05	0.000652	CcSEcCtD
Alprostadil—Dermatitis—Sitagliptin—type 2 diabetes mellitus	9.6e-05	0.000652	CcSEcCtD
Alprostadil—Headache—Glimepiride—type 2 diabetes mellitus	9.58e-05	0.00065	CcSEcCtD
Alprostadil—Cough—Irbesartan—type 2 diabetes mellitus	9.56e-05	0.000649	CcSEcCtD
Alprostadil—Headache—Sitagliptin—type 2 diabetes mellitus	9.55e-05	0.000648	CcSEcCtD
Alprostadil—Anaemia—Losartan—type 2 diabetes mellitus	9.53e-05	0.000647	CcSEcCtD
Alprostadil—Oedema—Metformin—type 2 diabetes mellitus	9.47e-05	0.000643	CcSEcCtD
Alprostadil—Hypertension—Irbesartan—type 2 diabetes mellitus	9.46e-05	0.000642	CcSEcCtD
Alprostadil—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	9.44e-05	0.000641	CcSEcCtD
Alprostadil—Flushing—Ramipril—type 2 diabetes mellitus	9.42e-05	0.00064	CcSEcCtD
Alprostadil—Infection—Metformin—type 2 diabetes mellitus	9.41e-05	0.000639	CcSEcCtD
Alprostadil—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	9.33e-05	0.000633	CcSEcCtD
Alprostadil—Shock—Metformin—type 2 diabetes mellitus	9.32e-05	0.000633	CcSEcCtD
Alprostadil—Thrombocytopenia—Metformin—type 2 diabetes mellitus	9.27e-05	0.00063	CcSEcCtD
Alprostadil—Syncope—Losartan—type 2 diabetes mellitus	9.24e-05	0.000628	CcSEcCtD
Alprostadil—Discomfort—Irbesartan—type 2 diabetes mellitus	9.21e-05	0.000625	CcSEcCtD
Alprostadil—Skin disorder—Metformin—type 2 diabetes mellitus	9.2e-05	0.000625	CcSEcCtD
Alprostadil—Hyperhidrosis—Metformin—type 2 diabetes mellitus	9.16e-05	0.000622	CcSEcCtD
Alprostadil—Dyspepsia—Valsartan—type 2 diabetes mellitus	9.16e-05	0.000622	CcSEcCtD
Alprostadil—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.12e-05	0.000619	CcSEcCtD
Alprostadil—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.12e-05	0.000619	CcSEcCtD
Alprostadil—Nausea—Glimepiride—type 2 diabetes mellitus	9.08e-05	0.000617	CcSEcCtD
Alprostadil—Loss of consciousness—Losartan—type 2 diabetes mellitus	9.06e-05	0.000615	CcSEcCtD
Alprostadil—Nausea—Sitagliptin—type 2 diabetes mellitus	9.05e-05	0.000615	CcSEcCtD
Alprostadil—Dyspepsia—Orlistat—type 2 diabetes mellitus	9.05e-05	0.000614	CcSEcCtD
Alprostadil—Asthenia—Glyburide—type 2 diabetes mellitus	9.05e-05	0.000614	CcSEcCtD
Alprostadil—Cough—Losartan—type 2 diabetes mellitus	8.99e-05	0.000611	CcSEcCtD
Alprostadil—Body temperature increased—Gliclazide—type 2 diabetes mellitus	8.95e-05	0.000608	CcSEcCtD
Alprostadil—Abdominal pain—Gliclazide—type 2 diabetes mellitus	8.95e-05	0.000608	CcSEcCtD
Alprostadil—Oedema—Irbesartan—type 2 diabetes mellitus	8.94e-05	0.000607	CcSEcCtD
Alprostadil—Pruritus—Glyburide—type 2 diabetes mellitus	8.92e-05	0.000606	CcSEcCtD
Alprostadil—Infection—Irbesartan—type 2 diabetes mellitus	8.88e-05	0.000603	CcSEcCtD
Alprostadil—Hypotension—Metformin—type 2 diabetes mellitus	8.85e-05	0.000601	CcSEcCtD
Alprostadil—Erythema—Ramipril—type 2 diabetes mellitus	8.84e-05	0.0006	CcSEcCtD
Alprostadil—Shock—Irbesartan—type 2 diabetes mellitus	8.79e-05	0.000597	CcSEcCtD
Alprostadil—Pain—Orlistat—type 2 diabetes mellitus	8.79e-05	0.000597	CcSEcCtD
Alprostadil—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	8.75e-05	0.000594	CcSEcCtD
Alprostadil—Tachycardia—Irbesartan—type 2 diabetes mellitus	8.72e-05	0.000592	CcSEcCtD
Alprostadil—Rash—Bromocriptine—type 2 diabetes mellitus	8.7e-05	0.00059	CcSEcCtD
Alprostadil—Dermatitis—Bromocriptine—type 2 diabetes mellitus	8.69e-05	0.00059	CcSEcCtD
Alprostadil—Skin disorder—Irbesartan—type 2 diabetes mellitus	8.68e-05	0.000589	CcSEcCtD
Alprostadil—Discomfort—Losartan—type 2 diabetes mellitus	8.67e-05	0.000589	CcSEcCtD
Alprostadil—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	8.64e-05	0.000587	CcSEcCtD
Alprostadil—Headache—Bromocriptine—type 2 diabetes mellitus	8.64e-05	0.000587	CcSEcCtD
Alprostadil—Diarrhoea—Glyburide—type 2 diabetes mellitus	8.63e-05	0.000586	CcSEcCtD
Alprostadil—Nervousness—Ramipril—type 2 diabetes mellitus	8.58e-05	0.000583	CcSEcCtD
Alprostadil—Dry mouth—Losartan—type 2 diabetes mellitus	8.58e-05	0.000583	CcSEcCtD
Alprostadil—Muscle spasms—Ramipril—type 2 diabetes mellitus	8.5e-05	0.000577	CcSEcCtD
Alprostadil—Feeling abnormal—Orlistat—type 2 diabetes mellitus	8.47e-05	0.000575	CcSEcCtD
Alprostadil—Oedema—Losartan—type 2 diabetes mellitus	8.41e-05	0.000571	CcSEcCtD
Alprostadil—Infection—Losartan—type 2 diabetes mellitus	8.36e-05	0.000567	CcSEcCtD
Alprostadil—Hypotension—Irbesartan—type 2 diabetes mellitus	8.35e-05	0.000567	CcSEcCtD
Alprostadil—Dyspepsia—Metformin—type 2 diabetes mellitus	8.34e-05	0.000566	CcSEcCtD
Alprostadil—Shock—Losartan—type 2 diabetes mellitus	8.28e-05	0.000562	CcSEcCtD
Alprostadil—Thrombocytopenia—Losartan—type 2 diabetes mellitus	8.24e-05	0.000559	CcSEcCtD
Alprostadil—Abdominal pain—Valsartan—type 2 diabetes mellitus	8.22e-05	0.000558	CcSEcCtD
Alprostadil—Tachycardia—Losartan—type 2 diabetes mellitus	8.21e-05	0.000557	CcSEcCtD
Alprostadil—Nausea—Bromocriptine—type 2 diabetes mellitus	8.19e-05	0.000556	CcSEcCtD
Alprostadil—Hyperhidrosis—Losartan—type 2 diabetes mellitus	8.13e-05	0.000552	CcSEcCtD
Alprostadil—Body temperature increased—Orlistat—type 2 diabetes mellitus	8.12e-05	0.000552	CcSEcCtD
Alprostadil—Abdominal pain—Orlistat—type 2 diabetes mellitus	8.12e-05	0.000552	CcSEcCtD
Alprostadil—Asthenia—Gliclazide—type 2 diabetes mellitus	8.12e-05	0.000551	CcSEcCtD
Alprostadil—Pruritus—Gliclazide—type 2 diabetes mellitus	8.01e-05	0.000544	CcSEcCtD
Alprostadil—Rash—Glyburide—type 2 diabetes mellitus	7.95e-05	0.00054	CcSEcCtD
Alprostadil—Dermatitis—Glyburide—type 2 diabetes mellitus	7.94e-05	0.000539	CcSEcCtD
Alprostadil—Syncope—Ramipril—type 2 diabetes mellitus	7.93e-05	0.000538	CcSEcCtD
Alprostadil—Headache—Glyburide—type 2 diabetes mellitus	7.9e-05	0.000536	CcSEcCtD
Alprostadil—Dyspepsia—Irbesartan—type 2 diabetes mellitus	7.87e-05	0.000534	CcSEcCtD
Alprostadil—Hypotension—Losartan—type 2 diabetes mellitus	7.86e-05	0.000534	CcSEcCtD
Alprostadil—Feeling abnormal—Metformin—type 2 diabetes mellitus	7.81e-05	0.00053	CcSEcCtD
Alprostadil—Loss of consciousness—Ramipril—type 2 diabetes mellitus	7.77e-05	0.000527	CcSEcCtD
Alprostadil—Diarrhoea—Gliclazide—type 2 diabetes mellitus	7.75e-05	0.000526	CcSEcCtD
Alprostadil—Cough—Ramipril—type 2 diabetes mellitus	7.71e-05	0.000524	CcSEcCtD
Alprostadil—Convulsion—Ramipril—type 2 diabetes mellitus	7.66e-05	0.00052	CcSEcCtD
Alprostadil—Pain—Irbesartan—type 2 diabetes mellitus	7.64e-05	0.000519	CcSEcCtD
Alprostadil—Nausea—Glyburide—type 2 diabetes mellitus	7.49e-05	0.000508	CcSEcCtD
Alprostadil—Abdominal pain—Metformin—type 2 diabetes mellitus	7.49e-05	0.000508	CcSEcCtD
Alprostadil—Dizziness—Gliclazide—type 2 diabetes mellitus	7.49e-05	0.000508	CcSEcCtD
Alprostadil—Asthenia—Valsartan—type 2 diabetes mellitus	7.46e-05	0.000507	CcSEcCtD
Alprostadil—Discomfort—Ramipril—type 2 diabetes mellitus	7.43e-05	0.000505	CcSEcCtD
Alprostadil—Dyspepsia—Losartan—type 2 diabetes mellitus	7.4e-05	0.000503	CcSEcCtD
Alprostadil—Asthenia—Orlistat—type 2 diabetes mellitus	7.37e-05	0.000501	CcSEcCtD
Alprostadil—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	7.37e-05	0.0005	CcSEcCtD
Alprostadil—Pruritus—Valsartan—type 2 diabetes mellitus	7.36e-05	0.0005	CcSEcCtD
Alprostadil—Dry mouth—Ramipril—type 2 diabetes mellitus	7.36e-05	0.0005	CcSEcCtD
Alprostadil—Pruritus—Orlistat—type 2 diabetes mellitus	7.27e-05	0.000494	CcSEcCtD
Alprostadil—Oedema—Ramipril—type 2 diabetes mellitus	7.21e-05	0.00049	CcSEcCtD
Alprostadil—Pain—Losartan—type 2 diabetes mellitus	7.19e-05	0.000488	CcSEcCtD
Alprostadil—Rash—Gliclazide—type 2 diabetes mellitus	7.14e-05	0.000485	CcSEcCtD
Alprostadil—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.13e-05	0.000484	CcSEcCtD
Alprostadil—Diarrhoea—Valsartan—type 2 diabetes mellitus	7.12e-05	0.000483	CcSEcCtD
Alprostadil—Shock—Ramipril—type 2 diabetes mellitus	7.1e-05	0.000482	CcSEcCtD
Alprostadil—Headache—Gliclazide—type 2 diabetes mellitus	7.09e-05	0.000482	CcSEcCtD
Alprostadil—Abdominal pain—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.00048	CcSEcCtD
Alprostadil—Body temperature increased—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.00048	CcSEcCtD
Alprostadil—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	7.06e-05	0.00048	CcSEcCtD
Alprostadil—Tachycardia—Ramipril—type 2 diabetes mellitus	7.04e-05	0.000478	CcSEcCtD
Alprostadil—Diarrhoea—Orlistat—type 2 diabetes mellitus	7.03e-05	0.000477	CcSEcCtD
Alprostadil—Skin disorder—Ramipril—type 2 diabetes mellitus	7.01e-05	0.000476	CcSEcCtD
Alprostadil—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	6.97e-05	0.000473	CcSEcCtD
Alprostadil—Feeling abnormal—Losartan—type 2 diabetes mellitus	6.93e-05	0.000471	CcSEcCtD
Alprostadil—Dizziness—Valsartan—type 2 diabetes mellitus	6.88e-05	0.000467	CcSEcCtD
Alprostadil—Dizziness—Orlistat—type 2 diabetes mellitus	6.8e-05	0.000461	CcSEcCtD
Alprostadil—Asthenia—Metformin—type 2 diabetes mellitus	6.8e-05	0.000461	CcSEcCtD
Alprostadil—Hypotension—Ramipril—type 2 diabetes mellitus	6.74e-05	0.000458	CcSEcCtD
Alprostadil—Nausea—Gliclazide—type 2 diabetes mellitus	6.72e-05	0.000457	CcSEcCtD
Alprostadil—Pruritus—Metformin—type 2 diabetes mellitus	6.7e-05	0.000455	CcSEcCtD
Alprostadil—Abdominal pain—Losartan—type 2 diabetes mellitus	6.65e-05	0.000452	CcSEcCtD
Alprostadil—Body temperature increased—Losartan—type 2 diabetes mellitus	6.65e-05	0.000452	CcSEcCtD
Alprostadil—Rash—Valsartan—type 2 diabetes mellitus	6.56e-05	0.000445	CcSEcCtD
Alprostadil—Dermatitis—Valsartan—type 2 diabetes mellitus	6.55e-05	0.000445	CcSEcCtD
Alprostadil—Headache—Valsartan—type 2 diabetes mellitus	6.52e-05	0.000442	CcSEcCtD
Alprostadil—Diarrhoea—Metformin—type 2 diabetes mellitus	6.48e-05	0.00044	CcSEcCtD
Alprostadil—Rash—Orlistat—type 2 diabetes mellitus	6.48e-05	0.00044	CcSEcCtD
Alprostadil—Dermatitis—Orlistat—type 2 diabetes mellitus	6.47e-05	0.00044	CcSEcCtD
Alprostadil—Headache—Orlistat—type 2 diabetes mellitus	6.44e-05	0.000437	CcSEcCtD
Alprostadil—Asthenia—Irbesartan—type 2 diabetes mellitus	6.41e-05	0.000435	CcSEcCtD
Alprostadil—Dyspepsia—Ramipril—type 2 diabetes mellitus	6.35e-05	0.000431	CcSEcCtD
Alprostadil—Pruritus—Irbesartan—type 2 diabetes mellitus	6.32e-05	0.000429	CcSEcCtD
Alprostadil—Dizziness—Metformin—type 2 diabetes mellitus	6.26e-05	0.000425	CcSEcCtD
Alprostadil—Nausea—Valsartan—type 2 diabetes mellitus	6.18e-05	0.000419	CcSEcCtD
Alprostadil—Diarrhoea—Irbesartan—type 2 diabetes mellitus	6.12e-05	0.000415	CcSEcCtD
Alprostadil—Nausea—Orlistat—type 2 diabetes mellitus	6.1e-05	0.000414	CcSEcCtD
Alprostadil—Asthenia—Losartan—type 2 diabetes mellitus	6.04e-05	0.00041	CcSEcCtD
Alprostadil—Rash—Metformin—type 2 diabetes mellitus	5.97e-05	0.000405	CcSEcCtD
Alprostadil—Dermatitis—Metformin—type 2 diabetes mellitus	5.97e-05	0.000405	CcSEcCtD
Alprostadil—Pruritus—Losartan—type 2 diabetes mellitus	5.95e-05	0.000404	CcSEcCtD
Alprostadil—Feeling abnormal—Ramipril—type 2 diabetes mellitus	5.94e-05	0.000404	CcSEcCtD
Alprostadil—Headache—Metformin—type 2 diabetes mellitus	5.93e-05	0.000403	CcSEcCtD
Alprostadil—Dizziness—Irbesartan—type 2 diabetes mellitus	5.91e-05	0.000401	CcSEcCtD
Alprostadil—Diarrhoea—Losartan—type 2 diabetes mellitus	5.76e-05	0.000391	CcSEcCtD
Alprostadil—Body temperature increased—Ramipril—type 2 diabetes mellitus	5.7e-05	0.000387	CcSEcCtD
Alprostadil—Abdominal pain—Ramipril—type 2 diabetes mellitus	5.7e-05	0.000387	CcSEcCtD
Alprostadil—Rash—Irbesartan—type 2 diabetes mellitus	5.64e-05	0.000383	CcSEcCtD
Alprostadil—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.000382	CcSEcCtD
Alprostadil—Nausea—Metformin—type 2 diabetes mellitus	5.63e-05	0.000382	CcSEcCtD
Alprostadil—Headache—Irbesartan—type 2 diabetes mellitus	5.6e-05	0.00038	CcSEcCtD
Alprostadil—Dizziness—Losartan—type 2 diabetes mellitus	5.56e-05	0.000378	CcSEcCtD
Alprostadil—Nausea—Irbesartan—type 2 diabetes mellitus	5.31e-05	0.00036	CcSEcCtD
Alprostadil—Rash—Losartan—type 2 diabetes mellitus	5.3e-05	0.00036	CcSEcCtD
Alprostadil—Dermatitis—Losartan—type 2 diabetes mellitus	5.3e-05	0.00036	CcSEcCtD
Alprostadil—Headache—Losartan—type 2 diabetes mellitus	5.27e-05	0.000358	CcSEcCtD
Alprostadil—Asthenia—Ramipril—type 2 diabetes mellitus	5.18e-05	0.000351	CcSEcCtD
Alprostadil—Pruritus—Ramipril—type 2 diabetes mellitus	5.1e-05	0.000346	CcSEcCtD
Alprostadil—Nausea—Losartan—type 2 diabetes mellitus	5e-05	0.000339	CcSEcCtD
Alprostadil—Diarrhoea—Ramipril—type 2 diabetes mellitus	4.94e-05	0.000335	CcSEcCtD
Alprostadil—Dizziness—Ramipril—type 2 diabetes mellitus	4.77e-05	0.000324	CcSEcCtD
Alprostadil—Rash—Ramipril—type 2 diabetes mellitus	4.55e-05	0.000309	CcSEcCtD
Alprostadil—Dermatitis—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000309	CcSEcCtD
Alprostadil—Headache—Ramipril—type 2 diabetes mellitus	4.52e-05	0.000307	CcSEcCtD
Alprostadil—Nausea—Ramipril—type 2 diabetes mellitus	4.28e-05	0.000291	CcSEcCtD
Alprostadil—ABCC5—Metabolism—CTGF—type 2 diabetes mellitus	1.62e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LPL—type 2 diabetes mellitus	1.62e-05	0.000149	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—CALM1—type 2 diabetes mellitus	1.62e-05	0.000149	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMGCR—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.61e-05	0.000148	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—APOA1—type 2 diabetes mellitus	1.59e-05	0.000147	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.58e-05	0.000146	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.58e-05	0.000146	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.58e-05	0.000146	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.58e-05	0.000145	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADRA2A—type 2 diabetes mellitus	1.57e-05	0.000145	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.56e-05	0.000144	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.56e-05	0.000144	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.56e-05	0.000143	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.56e-05	0.000143	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.56e-05	0.000143	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.56e-05	0.000143	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TGFB1—type 2 diabetes mellitus	1.55e-05	0.000143	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.53e-05	0.000141	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.53e-05	0.000141	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PRKCB—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.52e-05	0.00014	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP2E1—type 2 diabetes mellitus	1.51e-05	0.000139	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.5e-05	0.000139	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.5e-05	0.000139	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS2—type 2 diabetes mellitus	1.5e-05	0.000138	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SRC—type 2 diabetes mellitus	1.5e-05	0.000138	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC2A1—type 2 diabetes mellitus	1.49e-05	0.000138	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP1A2—type 2 diabetes mellitus	1.49e-05	0.000138	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.49e-05	0.000137	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFBR2—type 2 diabetes mellitus	1.49e-05	0.000137	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—PPARA—type 2 diabetes mellitus	1.47e-05	0.000135	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.46e-05	0.000135	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.46e-05	0.000135	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—type 2 diabetes mellitus	1.46e-05	0.000134	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CYP3A4—type 2 diabetes mellitus	1.46e-05	0.000134	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—C3—type 2 diabetes mellitus	1.46e-05	0.000134	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CDKN2B—type 2 diabetes mellitus	1.44e-05	0.000133	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GCG—type 2 diabetes mellitus	1.43e-05	0.000132	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SLC2A4—type 2 diabetes mellitus	1.43e-05	0.000132	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.42e-05	0.00013	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.42e-05	0.00013	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.41e-05	0.00013	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.41e-05	0.00013	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOB—type 2 diabetes mellitus	1.41e-05	0.000129	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GCG—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GCG—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.39e-05	0.000128	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AGT—type 2 diabetes mellitus	1.38e-05	0.000127	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	1.38e-05	0.000127	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.37e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.37e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.37e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.37e-05	0.000126	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.36e-05	0.000125	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—LEP—type 2 diabetes mellitus	1.36e-05	0.000125	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOE—type 2 diabetes mellitus	1.36e-05	0.000125	CbGpPWpGaD
Alprostadil—ABCC5—Disease—LPL—type 2 diabetes mellitus	1.34e-05	0.000124	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.34e-05	0.000123	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TGFB1—type 2 diabetes mellitus	1.34e-05	0.000123	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—type 2 diabetes mellitus	1.33e-05	0.000123	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT2—type 2 diabetes mellitus	1.33e-05	0.000122	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ADCY5—type 2 diabetes mellitus	1.31e-05	0.000121	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.3e-05	0.00012	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.3e-05	0.00012	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.28e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.28e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.28e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.28e-05	0.000118	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.28e-05	0.000118	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SERPINE1—type 2 diabetes mellitus	1.26e-05	0.000116	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—ALB—type 2 diabetes mellitus	1.26e-05	0.000116	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PPP2CA—type 2 diabetes mellitus	1.26e-05	0.000116	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CCR5—type 2 diabetes mellitus	1.24e-05	0.000114	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GNB3—type 2 diabetes mellitus	1.23e-05	0.000114	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.23e-05	0.000114	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—HMOX1—type 2 diabetes mellitus	1.23e-05	0.000113	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CAT—type 2 diabetes mellitus	1.21e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.21e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.21e-05	0.000112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.21e-05	0.000111	CbGpPWpGaD
Alprostadil—ABCC5—Disease—MTHFR—type 2 diabetes mellitus	1.21e-05	0.000111	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PIK3R1—type 2 diabetes mellitus	1.21e-05	0.000111	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—NOS3—type 2 diabetes mellitus	1.21e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.2e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.2e-05	0.000111	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AVP—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AVP—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.18e-05	0.000109	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOB—type 2 diabetes mellitus	1.18e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.17e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.17e-05	0.000108	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.16e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.16e-05	0.000107	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—INS—type 2 diabetes mellitus	1.16e-05	0.000107	CbGpPWpGaD
Alprostadil—ABCC5—Disease—HIF1A—type 2 diabetes mellitus	1.15e-05	0.000106	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS2—type 2 diabetes mellitus	1.15e-05	0.000106	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTM1—type 2 diabetes mellitus	1.15e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOB—type 2 diabetes mellitus	1.15e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOB—type 2 diabetes mellitus	1.15e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.14e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.14e-05	0.000105	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.14e-05	0.000105	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CALM1—type 2 diabetes mellitus	1.13e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.13e-05	0.000104	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.13e-05	0.000104	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOE—type 2 diabetes mellitus	1.13e-05	0.000104	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—LPL—type 2 diabetes mellitus	1.12e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.12e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.12e-05	0.000103	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	1.12e-05	0.000103	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOA1—type 2 diabetes mellitus	1.11e-05	0.000102	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ADCY5—type 2 diabetes mellitus	1.1e-05	0.000101	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GPX1—type 2 diabetes mellitus	1.1e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LPL—type 2 diabetes mellitus	1.09e-05	0.000101	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LPL—type 2 diabetes mellitus	1.09e-05	0.000101	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	1.09e-05	0.000101	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—AKT1—type 2 diabetes mellitus	1.08e-05	9.91e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.07e-05	9.85e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.07e-05	9.85e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CD36—type 2 diabetes mellitus	1.07e-05	9.83e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.06e-05	9.8e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPP2CA—type 2 diabetes mellitus	1.05e-05	9.71e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS2—type 2 diabetes mellitus	1.05e-05	9.65e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.03e-05	9.44e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.03e-05	9.44e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.02e-05	9.36e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.02e-05	9.36e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—MTHFR—type 2 diabetes mellitus	1.01e-05	9.32e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.01e-05	9.27e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.01e-05	9.27e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IRS1—type 2 diabetes mellitus	1e-05	9.24e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARA—type 2 diabetes mellitus	9.93e-06	9.14e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—C3—type 2 diabetes mellitus	9.84e-06	9.06e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—C3—type 2 diabetes mellitus	9.84e-06	9.06e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AGT—type 2 diabetes mellitus	9.62e-06	8.85e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—INS—type 2 diabetes mellitus	9.61e-06	8.85e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RELA—type 2 diabetes mellitus	9.57e-06	8.81e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CALM1—type 2 diabetes mellitus	9.46e-06	8.71e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOE—type 2 diabetes mellitus	9.42e-06	8.67e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.39e-06	8.64e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.39e-06	8.64e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.36e-06	8.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.36e-06	8.62e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AGT—type 2 diabetes mellitus	9.35e-06	8.61e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AGT—type 2 diabetes mellitus	9.35e-06	8.61e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOA1—type 2 diabetes mellitus	9.32e-06	8.58e-05	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—AKT1—type 2 diabetes mellitus	9.31e-06	8.57e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT2—type 2 diabetes mellitus	9.29e-06	8.55e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.2e-06	8.46e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CALM1—type 2 diabetes mellitus	9.2e-06	8.46e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOE—type 2 diabetes mellitus	9.16e-06	8.44e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—LEP—type 2 diabetes mellitus	9.16e-06	8.44e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOE—type 2 diabetes mellitus	9.16e-06	8.44e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—LEP—type 2 diabetes mellitus	9.16e-06	8.44e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.06e-06	8.34e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOA1—type 2 diabetes mellitus	9.06e-06	8.34e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SRC—type 2 diabetes mellitus	8.93e-06	8.22e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SERPINE1—type 2 diabetes mellitus	8.83e-06	8.13e-05	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	8.71e-06	8.02e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—type 2 diabetes mellitus	8.7e-06	8e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.64e-06	7.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.64e-06	7.95e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—type 2 diabetes mellitus	8.63e-06	7.94e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—IL6—type 2 diabetes mellitus	8.57e-06	7.89e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—NOS3—type 2 diabetes mellitus	8.43e-06	7.76e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PIK3R1—type 2 diabetes mellitus	8.43e-06	7.76e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PPARG—type 2 diabetes mellitus	8.21e-06	7.56e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.18e-06	7.52e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IRS1—type 2 diabetes mellitus	8.18e-06	7.52e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—type 2 diabetes mellitus	8.15e-06	7.51e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	8.07e-06	7.43e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—INS—type 2 diabetes mellitus	8.05e-06	7.41e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TGFB1—type 2 diabetes mellitus	7.98e-06	7.35e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	7.91e-06	7.28e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—INS—type 2 diabetes mellitus	7.83e-06	7.21e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—INS—type 2 diabetes mellitus	7.83e-06	7.21e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—type 2 diabetes mellitus	7.71e-06	7.1e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.7e-06	7.09e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.7e-06	7.09e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.57e-06	6.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.57e-06	6.97e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.57e-06	6.97e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.57e-06	6.97e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.54e-06	6.94e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.54e-06	6.94e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SRC—type 2 diabetes mellitus	7.52e-06	6.92e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—ALB—type 2 diabetes mellitus	7.38e-06	6.79e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	7.32e-06	6.74e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.19e-06	6.62e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.19e-06	6.62e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—NOS3—type 2 diabetes mellitus	7.06e-06	6.5e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PIK3R1—type 2 diabetes mellitus	7.06e-06	6.5e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.87e-06	6.32e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.87e-06	6.32e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.87e-06	6.32e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.87e-06	6.32e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.72e-06	6.19e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.59e-06	6.07e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RELA—type 2 diabetes mellitus	6.46e-06	5.95e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RELA—type 2 diabetes mellitus	6.46e-06	5.95e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—type 2 diabetes mellitus	6.46e-06	5.94e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—SRC—type 2 diabetes mellitus	6.24e-06	5.74e-05	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.88e-06	5.42e-05	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.88e-06	5.42e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.83e-06	5.37e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.83e-06	5.37e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.79e-06	5.33e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.79e-06	5.33e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TGFB1—type 2 diabetes mellitus	5.58e-06	5.13e-05	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—AKT1—type 2 diabetes mellitus	5.55e-06	5.11e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.51e-06	5.07e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.51e-06	5.07e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—EGFR—type 2 diabetes mellitus	5.47e-06	5.03e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.45e-06	5.02e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.45e-06	5.02e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.34e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.34e-06	4.92e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SRC—type 2 diabetes mellitus	5.08e-06	4.67e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SRC—type 2 diabetes mellitus	5.08e-06	4.67e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IL6—type 2 diabetes mellitus	5.06e-06	4.66e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.95e-06	4.55e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.95e-06	4.55e-05	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.67e-06	4.3e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.54e-06	4.18e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.54e-06	4.18e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.45e-06	4.1e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.45e-06	4.1e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—IL6—type 2 diabetes mellitus	4.2e-06	3.87e-05	CbGpPWpGaD
Alprostadil—ABCC5—Disease—AKT1—type 2 diabetes mellitus	3.88e-06	3.57e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.42e-06	3.15e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IL6—type 2 diabetes mellitus	3.42e-06	3.15e-05	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—AKT1—type 2 diabetes mellitus	3.25e-06	2.99e-05	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.16e-06	2.9e-05	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.16e-06	2.9e-05	CbGpPWpGaD
